Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome
A Phase 1, Open-label, Dose-escalation Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Status: Enrolling
Updated:  2/9/2016
University of Pittsburgh Cancer Institute / Hillman Cancer Center
mi
from
Pittsburgh, PA
Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome
A Phase 1, Open-label, Dose-escalation Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Status: Enrolling
Updated: 2/9/2016
University of Pittsburgh Cancer Institute / Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
The Utility of Peri-operative Arnica Montana for Reduction of Ecchymosis in Rhinoplasty Surgery
The Utility of Peri-operative Arnica Montana for Reduction of Ecchymosis in Rhinoplasty Surgery
Status: Enrolling
Updated:  2/9/2016
University of Wisconsin-Madison
mi
from
Madison, WI
The Utility of Peri-operative Arnica Montana for Reduction of Ecchymosis in Rhinoplasty Surgery
The Utility of Peri-operative Arnica Montana for Reduction of Ecchymosis in Rhinoplasty Surgery
Status: Enrolling
Updated: 2/9/2016
University of Wisconsin-Madison
mi
from
Madison, WI
Click here to add this to my saved trials
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  2/11/2016
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 2/11/2016
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  2/11/2016
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 2/11/2016
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  2/11/2016
Karmanos Cancer Institute
mi
from
Detroit, MI
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 2/11/2016
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  2/11/2016
Fox Chase Cancer Center
mi
from
Philadelphia, PA
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 2/11/2016
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  2/11/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 2/11/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant
Maintenance Therapy With Decitabine After Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome
Status: Enrolling
Updated:  2/11/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant
Maintenance Therapy With Decitabine After Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome
Status: Enrolling
Updated: 2/11/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Blood Samples From Patients With Cancer Treated on a Clinical Trial to Control Nausea and Vomiting During Donor Stem Cell Transplant
Substance P Follow-up to a Pilot Study of Aprepitant vs Placebo Combined With Standard Antiemetics for the Control of Nausea and Vomiting During Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  2/11/2016
OHSU Knight Cancer Institute
mi
from
Portland, OR
Blood Samples From Patients With Cancer Treated on a Clinical Trial to Control Nausea and Vomiting During Donor Stem Cell Transplant
Substance P Follow-up to a Pilot Study of Aprepitant vs Placebo Combined With Standard Antiemetics for the Control of Nausea and Vomiting During Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 2/11/2016
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma
Phase II Study of SOM230 LAR in Combination With Bortezomib and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated:  2/11/2016
Hillman Cancer Center
mi
from
Pittsburgh, PA
SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma
Phase II Study of SOM230 LAR in Combination With Bortezomib and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status: Enrolling
Updated: 2/11/2016
Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
1068GCC Evaluate Efficacy & Explore Mechanism of Acupuncture in Treating Bortezomib-induced Peripheral Neuropathy (BIPN) in Multiple Myeloma
A Pilot Study to Evaluate the Efficacy and Explore the Mechanism of Acupuncture in Treating Bortezomib-induced Peripheral Neuropathy (BIPN) in Multiple Myeloma Patients
Status: Enrolling
Updated:  2/12/2016
University of Maryland/Marlene and Stewart Greenebaum Cancer Center
mi
from
Baltimore, MD
1068GCC Evaluate Efficacy & Explore Mechanism of Acupuncture in Treating Bortezomib-induced Peripheral Neuropathy (BIPN) in Multiple Myeloma
A Pilot Study to Evaluate the Efficacy and Explore the Mechanism of Acupuncture in Treating Bortezomib-induced Peripheral Neuropathy (BIPN) in Multiple Myeloma Patients
Status: Enrolling
Updated: 2/12/2016
University of Maryland/Marlene and Stewart Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
Pilot Study Evaluating Aprepitant (MK-869) for Prevention of Nausea & Vomiting Secondary to High Dose Cyclophosphamide Administered to Patients Underging Undergoing Peripheral Hematopoietic Progenitor Cell Mobilization Prior to Autologous Transplantation
Status: Enrolling
Updated:  2/12/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
Pilot Study Evaluating Aprepitant (MK-869) for Prevention of Nausea & Vomiting Secondary to High Dose Cyclophosphamide Administered to Patients Underging Undergoing Peripheral Hematopoietic Progenitor Cell Mobilization Prior to Autologous Transplantation
Status: Enrolling
Updated: 2/12/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
A Phase II Study of Oral Clofarabine in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
Status: Enrolling
Updated:  2/16/2016
Massachusetts General Hospital
mi
from
Boston, MA
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
A Phase II Study of Oral Clofarabine in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
Status: Enrolling
Updated: 2/16/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
A Phase II Study of Oral Clofarabine in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
Status: Enrolling
Updated:  2/16/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
A Phase II Study of Oral Clofarabine in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
Status: Enrolling
Updated: 2/16/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase
A Phase I Dose Escalation Study of the Combination of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase
Status: Enrolling
Updated:  2/16/2016
Local Institution
mi
from
Los Angeles, CA
Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase
A Phase I Dose Escalation Study of the Combination of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase
Status: Enrolling
Updated: 2/16/2016
Local Institution
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase
A Phase I Dose Escalation Study of the Combination of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase
Status: Enrolling
Updated:  2/16/2016
Local Institution
mi
from
San Francisco, CA
Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase
A Phase I Dose Escalation Study of the Combination of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase
Status: Enrolling
Updated: 2/16/2016
Local Institution
mi
from
San Francisco, CA
Click here to add this to my saved trials
Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase
A Phase I Dose Escalation Study of the Combination of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase
Status: Enrolling
Updated:  2/16/2016
Local Institution
mi
from
New York, NY
Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase
A Phase I Dose Escalation Study of the Combination of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase
Status: Enrolling
Updated: 2/16/2016
Local Institution
mi
from
New York, NY
Click here to add this to my saved trials
Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia
Phase Ib Study Evaluating the Safety and Exploring the Molecular and Cytogenetic Response of Combination Therapy With Dasatinib and Ipilimumab in Patients With Chronic or Accelerated Phase Chronic Myeloid Leukemia
Status: Enrolling
Updated:  2/16/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia
Phase Ib Study Evaluating the Safety and Exploring the Molecular and Cytogenetic Response of Combination Therapy With Dasatinib and Ipilimumab in Patients With Chronic or Accelerated Phase Chronic Myeloid Leukemia
Status: Enrolling
Updated: 2/16/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma
Phase I/II Trial of Autologous Peripheral Blood Progenitor Cell Transplantation With VELCADE Maintenance as Treatment for Intermediate- and Advanced-Stage Multiple Myeloma
Status: Enrolling
Updated:  2/17/2016
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma
Phase I/II Trial of Autologous Peripheral Blood Progenitor Cell Transplantation With VELCADE Maintenance as Treatment for Intermediate- and Advanced-Stage Multiple Myeloma
Status: Enrolling
Updated: 2/17/2016
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
Phoenix Children's Hospital
mi
from
Phoenix, AZ
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
Scottsdale Medical Specialists
mi
from
Scottsdale, AZ
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
Scottsdale Medical Specialists
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
Arizona Oncology Associates
mi
from
Tucson, AZ
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
Arizona Oncology Associates
mi
from
Tucson, AZ
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
Scripps Cancer Center
mi
from
LaJolla, CA
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
Scripps Cancer Center
mi
from
LaJolla, CA
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
Kenmar Research Institute
mi
from
Los Angeles, CA
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
Kenmar Research Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
Children's Hospital of Orange County
mi
from
Orange, CA
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
Connecticut Children's Medical Center
mi
from
Hartford, CT
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
Connecticut Children's Medical Center
mi
from
Hartford, CT
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
Cancer Center of Central Connecticut
mi
from
Southington, CT
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
Cancer Center of Central Connecticut
mi
from
Southington, CT
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
Georgetown University
mi
from
Washington,
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
Georgetown University
mi
from
Washington,
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
VA Medical Center
mi
from
Washington,
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
VA Medical Center
mi
from
Washington,
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
Halifax Health Medical Center
mi
from
Daytona Beach, FL
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
Halifax Health Medical Center
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
Hematology Oncology Associates
mi
from
Lake Worth, FL
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
Hematology Oncology Associates
mi
from
Lake Worth, FL
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
Lakeland Regional Cancer Center
mi
from
Tampa, FL
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
Lakeland Regional Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
St. Joseph's Children's Hospital of Tampa
mi
from
Tampa, FL
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
St. Joseph's Children's Hospital of Tampa
mi
from
Tampa, FL
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
Cleveland Clinic Florida
mi
from
Weston, FL
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
Cleveland Clinic Florida
mi
from
Weston, FL
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
Emory University School of Medicine Winship Cancer Center
mi
from
Atlanta, GA
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
Emory University School of Medicine Winship Cancer Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
Advocate Hope Children's Hospital
mi
from
Oak Lawn, IL
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
Advocate Hope Children's Hospital
mi
from
Oak Lawn, IL
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
University of Iowa Children's Hospital
mi
from
Iowa City, IA
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
University of Iowa Children's Hospital
mi
from
Iowa City, IA
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
Children's Hospital
mi
from
New Orleans, LA
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
Children's Hospital
mi
from
New Orleans, LA
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
Kalamazoo Hematology & Oncology
mi
from
Kalamazoo, MI
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
Kalamazoo Hematology & Oncology
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
CTO Breslin Cancer Center/MSU/Great Lakes Cancer Institute
mi
from
Lansing, MI
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
CTO Breslin Cancer Center/MSU/Great Lakes Cancer Institute
mi
from
Lansing, MI
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
University of Mississippi
mi
from
Jackson, MS
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
University of Mississippi
mi
from
Jackson, MS
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
Capital Comprehensive Cancer Care Clinic
mi
from
Jefferson City, MO
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
Capital Comprehensive Cancer Care Clinic
mi
from
Jefferson City, MO
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
UMDNJ-RWJ Medical School
mi
from
New Brunswick, NJ
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
UMDNJ-RWJ Medical School
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
Mt. Sinai Medical Center
mi
from
New York, NY
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
Mt. Sinai Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
Children's Hospital, University of Oklahoma
mi
from
Oklahoma City, OK
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
Children's Hospital, University of Oklahoma
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
Western Pennsylvannia Hospital
mi
from
Pittsburgh, PA
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
Western Pennsylvannia Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
Baptist Cancer Center
mi
from
Beaumont, TX
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
Baptist Cancer Center
mi
from
Beaumont, TX
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
Cook Children's Medical Center
mi
from
Fort Worth, TX
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
Cook Children's Medical Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
Tyler Hematology Oncology PA
mi
from
Tyler, TX
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
Tyler Hematology Oncology PA
mi
from
Tyler, TX
Click here to add this to my saved trials
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
MCV Hospital
mi
from
Richmond, VA
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
MCV Hospital
mi
from
Richmond, VA
Click here to add this to my saved trials